1. Home
  2. INSM vs JBL Comparison

INSM vs JBL Comparison

Compare INSM & JBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • JBL
  • Stock Information
  • Founded
  • INSM 1988
  • JBL 1966
  • Country
  • INSM United States
  • JBL United States
  • Employees
  • INSM N/A
  • JBL N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • JBL Electrical Products
  • Sector
  • INSM Health Care
  • JBL Technology
  • Exchange
  • INSM Nasdaq
  • JBL Nasdaq
  • Market Cap
  • INSM 12.5B
  • JBL 12.1B
  • IPO Year
  • INSM 2000
  • JBL 1993
  • Fundamental
  • Price
  • INSM $72.27
  • JBL $121.60
  • Analyst Decision
  • INSM Strong Buy
  • JBL Strong Buy
  • Analyst Count
  • INSM 16
  • JBL 8
  • Target Price
  • INSM $82.00
  • JBL $145.86
  • AVG Volume (30 Days)
  • INSM 1.8M
  • JBL 1.9M
  • Earning Date
  • INSM 10-24-2024
  • JBL 09-26-2024
  • Dividend Yield
  • INSM N/A
  • JBL 0.26%
  • EPS Growth
  • INSM N/A
  • JBL 85.55
  • EPS
  • INSM N/A
  • JBL 11.17
  • Revenue
  • INSM $328,605,000.00
  • JBL $28,883,000,000.00
  • Revenue This Year
  • INSM $19.10
  • JBL N/A
  • Revenue Next Year
  • INSM $44.67
  • JBL $5.72
  • P/E Ratio
  • INSM N/A
  • JBL $10.86
  • Revenue Growth
  • INSM 21.94
  • JBL N/A
  • 52 Week Low
  • INSM $21.92
  • JBL $95.85
  • 52 Week High
  • INSM $80.53
  • JBL $156.94
  • Technical
  • Relative Strength Index (RSI)
  • INSM 46.30
  • JBL 65.92
  • Support Level
  • INSM $71.11
  • JBL $118.14
  • Resistance Level
  • INSM $73.81
  • JBL $120.69
  • Average True Range (ATR)
  • INSM 2.15
  • JBL 3.05
  • MACD
  • INSM -0.10
  • JBL 0.87
  • Stochastic Oscillator
  • INSM 36.26
  • JBL 65.01

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

About JBL Jabil Inc.

Jabil Inc is a United States-based company engaged in providing manufacturing services and solutions. It provides comprehensive electronics design, production and product management services to companies in various industries and end markets.The Company derives its revenue from providing comprehensive electronics design, production and product management services. It operates in two segments. The Electronics Manufacturing Services (EMS) segment, which is the key revenue driver, is focused on leveraging IT, supply chain design and engineering, technologies largely centered on core electronics. The Diversified Manufacturing Services (DMS) segment is focused on providing engineering solutions, with an emphasis on material sciences, technologies, and healthcare.

Share on Social Networks: